Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03873649 · ClinicalTrials.gov registry record
Immune Response in Hypersensitivity Pneumonitis
A clinical trial, sponsored by Nabeel Hamzeh.
- Completed
- Registry status
- 21
- Enrollment target
NCT03873649: Completed study, sponsored by Nabeel Hamzeh.
NCT03873649 is a clinical trial that has completed, run by Nabeel Hamzeh. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03873649 has completed, sponsored by Nabeel Hamzeh.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
Hypersensitivity pneumonitis (HP) is an inflammatory lung disease that is caused by exposure of susceptible individuals to organic materials in the environment. It is also known by various names depending on the exposure and some of these names include farmer's lung, pigeon breeder's lung, hot tub lung to name a few. HP can cause lung scarring that impairs breathing and oxygenation. Early detection and avoidance of triggers can stop and reverse the disease but a significant number of patients continue to have active disease requiring treatment in spite of avoiding the trigger. The current choice of therapies is based on clinical experience and not on rigorous clinical trials. Not fully understanding the type of inflammation that is seen in HP and the cells involved in this inflammatory response limits health care providers' ability to choose drugs to study in HP that can stop the inflammation and limit scar formation. The goal of the investigators' study is to better understand the type of cells that are involved in the inflammatory response in the lungs of HP patients and what drives these cells to be active. By better understanding the type of cells and what drives them, health care providers can begin to choose and study drugs that can limit the inflammation and subsequent scarring. The investigators' will recruit HP patients and with their consent perform a scope of the lungs (bronchoscopy) with a limited lung wash to get the inflamed cells out of the lungs to further study them in the lab. The investigators' study will provide us with preliminary results to guide us in performing a more detailed study in the future to better understand the disease.
Primary Outcome
T-cell subtypes will be determined by flow cytometry.
Interventions
- OTHER Bronchoscopy with lavage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-11-29 |
| Est. Completion | 2022-03-30 |
What the finished NCT03873649 record still lists
NCT03873649 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Bronchoscopy with lavage is the first listed.
NCT03873649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03873649 about?
NCT03873649 is a clinical study titled "Immune Response in Hypersensitivity Pneumonitis". Hypersensitivity pneumonitis (HP) is an inflammatory lung disease that is caused by exposure of susceptible individuals to organic materials in the environment. It is also known by various names depending on the exposure and some of these names include farmer's lung, pigeon breeder's lung, hot tub l...
What is the current status of trial NCT03873649?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2018-11-29. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT03873649?
The interventions under investigation include: Bronchoscopy with lavage (OTHER).
Who is sponsoring clinical trial NCT03873649?
This trial is sponsored by Nabeel Hamzeh, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI